Article
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
Author/s | González-Serna Martín, Manuel Alejandro
Corma Gómez, Anaïs Tellez, Francisco Ríos Villegas, MJ Corona Mata, D Merino, D Real Navarrete, Luis Miguel Macías Sánchez, Juan |
Department | Universidad de Sevilla. Departamento de Fisiología |
Publication Date | 2023-09-06 |
Deposit Date | 2024-05-15 |
Published in |
|
Abstract | HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials. |
Funding agencies | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) Instituto de Salud Carlos III Ministerio de Ciencia, Innovación y Universidades (MICINN). España European Commission. Fondo Social Europeo (FSO) Centro de Investigación Biomédica en Red Fundación para la Investigación en salud (FIS) del Instituto Carlos III |
Project ID. | PI018/00606
CP18/00146 PI22/01098 PI21/00793 PI18/01270 |
Citation | González-Serna Martín, M.A., Corma Gómez, A., Tellez, F., Ríos Villegas, M., Corona Mata, D., Merino, D.,...,Macías Sánchez, J. (2023). Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice. Journal of Antimicrobial Chemotherapy, 78 (10), 2591-2596. https://doi.org/10.1093/jac/dkad278. |
Files | Size | Format | View | Description |
---|---|---|---|---|
dkad278.pdf | 332.8Kb | [PDF] | View/ | |